Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial
about
Biological activity of lenalidomide and its underlying therapeutic effects in multiple myelomaNew criteria for response assessment: role of minimal residual disease in multiple myelomaA phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myelomaA phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaUpdate on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Immunomodulatory drugs in multiple myeloma.Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilitiesAn open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaThalidomide and its analogues in the treatment of Multiple MyelomaNovel agent induction therapy alone or followed by autologous stem cell transplantation in younger patients with multiple myeloma: A single-center retrospective study of 114 cases.Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma.Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.Multiple myeloma in the marrow: pathogenesis and treatments.A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myelomaBortezomib combination therapy in multiple myeloma.Sequential or combination therapy for multiple myeloma.Bortezomib for the treatment of previously untreated multiple myeloma.Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation.Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.Current approaches to the initial treatment of symptomatic multiple myeloma.Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma.Emerging stem cell therapies: treatment, safety, and biology.A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.Bortezomib for the treatment of multiple myeloma.Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
P2860
Q21285161-42D8C78B-27D0-4D30-A321-6BE48BAD8009Q27027512-E9967DFA-167D-4EDC-9013-645AD32BDAA7Q33399844-D431B7A0-CF54-4476-901E-9F9E9FA0A417Q33404007-5BB54B88-8950-4727-83AA-7F3D750DEA47Q33405532-016BCE6D-6EA8-4D60-A8A0-022A238C12D4Q33410297-DB5092E2-7362-4347-A8FA-D430863139A6Q33412684-A8FFAB74-D22A-42E4-968E-47D52682EE40Q34253548-94BD708C-C5A6-4268-B56F-24EFD728701CQ34325722-317681E3-2E8A-4958-A17B-662B5AA98546Q35569350-B74881D1-3091-491E-A057-593791265000Q35868171-17971AED-098E-4267-8001-C968436ACC01Q36012111-DC59CBB7-43C6-4F6C-878C-27F7409657D0Q36444523-6F93EEA2-BEB7-46EC-856D-99EE1F3A8A1BQ36502820-5ED16E77-9A17-4E5E-A2F9-DC6AA0E1FD09Q36541807-85A59198-1BFE-4590-A86E-EC3B55134DCBQ36592788-03229799-DC35-446C-A2A5-5217E1BD7F36Q36725401-2B815C2C-6C80-42B7-B9DF-6EBE5AA43A14Q37027114-2AEF6671-5525-489B-B35B-CE1D4E55E6B4Q38021041-ADD8579F-17D3-4B4C-9E25-BD95403D4430Q38059253-A68BEAA7-3C00-4406-A3AD-DA0AC997C56AQ38096055-A773E18B-2212-4740-B10B-F68371086CA4Q38413040-E47D9B76-5BD1-4509-B658-83A8BF73EE66Q38545607-005AF70D-949B-4298-803D-27BC9710D87FQ38738098-DB7D1DD1-331B-478C-BEE8-01DDF7711951Q38833538-C46911D2-3C82-44FA-939D-FA7215990836Q39524467-40ECCEE1-7129-4851-B8B0-93D6595572E7Q41819491-4E68FBDE-15D9-473E-B13F-5ADB4B5A38FDQ41849927-170A5BAA-9202-4957-B4A1-0941327C0DABQ41955327-A267E3F2-E142-4D3F-ACBC-BA82C30C9986Q42132657-9CE77F1D-053D-4F1F-AEDF-3526B25530DAQ42272171-8932A8C9-FD1F-4795-88CA-030325495D9CQ44469916-195D157C-D124-4D8F-8F3E-C8821443D9D0Q46147631-74CA851A-8248-4615-B84F-3E0B67CD9466Q47604607-832BEF38-96B7-448B-9AB4-1DABA37EA67DQ53522981-65F1A694-A3ED-4D6C-8E82-3AF2063E40F4
P2860
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Lenalidomide, bortezomib, pegy ...... loma Research Consortium trial
@ast
Lenalidomide, bortezomib, pegy ...... loma Research Consortium trial
@en
type
label
Lenalidomide, bortezomib, pegy ...... loma Research Consortium trial
@ast
Lenalidomide, bortezomib, pegy ...... loma Research Consortium trial
@en
prefLabel
Lenalidomide, bortezomib, pegy ...... loma Research Consortium trial
@ast
Lenalidomide, bortezomib, pegy ...... loma Research Consortium trial
@en
P2093
P2860
P50
P921
P1433
P1476
Lenalidomide, bortezomib, pegy ...... loma Research Consortium trial
@en
P2093
Andrzej J Jakubowiak
Colleen K Harvey
Craig C Hofmeister
Craig L Tendler
Dixie-Lee Esseltine
Donna E Reece
Erica L Campagnaro
Jacob P Laubach
Jennifer C Barrickman
Kent A Griffith
P2860
P304
P356
10.1182/BLOOD-2011-02-334755
P407
P577
2011-05-19T00:00:00Z